Use of Antidepressant Medications To Improve Outcomes After Stroke

  • F. CholletEmail author
  • B. Acket
  • N. Raposo
  • J. F. Albucher
  • I. Loubinoux
  • J. Pariente
Stroke (HP Adams Jr, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Stroke


Interest in the use of antidepressants after stroke has been renewed by better knowledge of poststroke depression, but mainly by the capacity of some of them to promote functional recovery of nondepressed subjects. Recombinant tissue plasminogen activator thrombolysis within the first few hours after the stroke is currently the only validated treatment able to improve the spontaneous—and most of the time incomplete—recovery of neurological functions after stroke. However, we have learned from research over the last decade, in part based on the considerable improvement of neuroimaging techniques, that spontaneous recovery of neurological functions is associated with a large intracerebral reorganization of the damaged human brain. The question of whether lesioned-brain plasticity can be modulated by external factors such as pharmacological antidepressant agents is now being addressed with the aim of improving recovery and reducing the final disability of patients. Poststroke depression is known to be frequent and deleterious for patient outcome. We review the interest in the use of antidepressants after stroke in classic but often neglected poststroke depression and we strongly underline the action of some antidepressants in promoting functional recovery of nondepressed patients after stroke.


Stroke Recovery Depression Antidepressants Fluoxetine Brain plasticity Motor function Monoaminergic drugs 



No potential conflicts of interest relevant to this article were reported.


Papers of particular interest, published recently, have been highlighted as: •• Of major importance

  1. 1.
    Loubinoux I, Chollet F. Neuropharmacology in stroke recovery. In: Cramer SC, Nudo RJ, editors. Brain repair after stroke. Cambridge: Cambridge University Press; 2010. p. 183–93.CrossRefGoogle Scholar
  2. 2.
    Goldstein LB. Influence of common drugs and related factors on stroke outcome. Curr Opin Neurol. 1997;10:52–7.PubMedCrossRefGoogle Scholar
  3. 3.
    Liepert J. Pharmacotherapy in restorative neurology. Current Opin Neurol. 2008;21:639–43.CrossRefGoogle Scholar
  4. 4.
    Hackett ML, Anderson CS, House A, Xia J. Interventions for treating depression after stroke. Cochrane Database of Systematic Reviews 2008, Issue 4. Art. No.: CD003437. doi: 10.1002/14651858.CD003437.pub3.
  5. 5.
    Chen Y, Patel NC, Guo JJ, Zhan S. Antidepressant prophylaxis for poststroke depression: a meta-analysis. Int Clin Psychopharmacol. 2007;22(3):159–66.PubMedCrossRefGoogle Scholar
  6. 6.
    •• Salter K, Bhogal S, Teasell R, Foley N, Speechley M. Post-stroke depression. The evidence-based review of stroke rehabilitation (EBRSR) Version 15. Exhaustive review of the relationships between stroke and depression.
  7. 7.
    Robinson RG. Poststroke depression: prevalence, diagnosis, treatment and disease progression. Biol Psychiatry. 2003;54:376–87.PubMedCrossRefGoogle Scholar
  8. 8.
    Farner L, Wagle J, Engedal K, Flekkoy KM, Wyller TB, Fure B. Depressive symptoms in stroke patients: a 13 month follow-up study of patients referred to a rehabilitation unit. J Affect Disord. 2010;127(1–3):211–8.PubMedCrossRefGoogle Scholar
  9. 9.
    Astrom M, Adolfsson R, Asplund K. Major depression in stroke patients: a 3-year longitudinal study. Stroke. 1993;24(7):976–82.PubMedCrossRefGoogle Scholar
  10. 10.
    Berg A, Psych L, Palomaki H, et al. Poststroke depression—an 18-month follow-up. Stroke. 2003;34(1):138–43.PubMedCrossRefGoogle Scholar
  11. 11.
    Paolucci S, Gandolfo C, Provinciali L, Torta R, Toso V. The Italian multicenter observational study on post-stroke depression (DESTRO). J Neurol. 2006;253:556–62.PubMedCrossRefGoogle Scholar
  12. 12.
    Paolucci S, Gandolfo C, Provinciali L, Torta R, Sommacal S, Toso V. Quantification of the risk of post-stroke depression: the Italian multicenter observational study DESTRO. Acta Psychiatr Scand. 2005;112:272–8.PubMedCrossRefGoogle Scholar
  13. 13.
    Hackett ML, Anderson CS. Frequency, management, and predictors of abnormal mood after stroke: the Auckland Regional Community Stroke (ARCOS) study, 2002 to 2003. Stroke. 2006;37:2123–8.PubMedCrossRefGoogle Scholar
  14. 14.
    Hackett ML, Anderson CS. Predictors of depression after stroke: a systematic review of observational studies. Stroke. 2005;36:2296–301.PubMedCrossRefGoogle Scholar
  15. 15.
    Bour A, Rasquin S, Aben I, Boreas A, Limburg M, Verhey F. A one-year follow-up study into the course of depression after stroke. J Nutr Health Aging. 2010;14:488–93.PubMedCrossRefGoogle Scholar
  16. 16.
    Carota A, Berney A, Aybek S, et al. A prospective study of predictors of poststroke depression. Neurology. 2005;64:428–33.PubMedCrossRefGoogle Scholar
  17. 17.
    Goodwin RD, Devanand DP. Stroke, depression, and functional health outcomes among adults in the community. J Geriatr Psychiatry Neurol. 2008;21:41–6.PubMedCrossRefGoogle Scholar
  18. 18.
    Van de Port I, Kwakkel G, van WI, Lindeman E. Susceptibility to deterioration of mobility long-term after stroke: a prospective cohort study. Stroke. 2006;37:167–71.PubMedCrossRefGoogle Scholar
  19. 19.
    Robinson RG, Schultz SK, Castillo C, Kopel T, Kosier JT, Newman RM, Curdue K, Petracca G, Starkstein SE. Nortriptyline versus fluoxetine in the treatment of depression and in short-term recovery after stroke: a placebo-controlled, double-blind study. Am J Psychiatry. 2000;157:351–9.PubMedCrossRefGoogle Scholar
  20. 20.
    Finklestein SP, Weintraub RJ, Karmouz N, Askinazi C, Davar G, Baldessarini RJ. Antidepressant drug treatment for post stroke depression: retrospective study. Arch Phys Med Rehabil. 1987;68:772–6.PubMedGoogle Scholar
  21. 21.
    Lauritzen L, Bendsen BB, Vilmar T, Bendsen EB, Lunde M, Bech P. Post-stroke depression: combined treatment with imipramine or desipramine and mianserin. A controlled clinical study. Psychopharmacology (Berl). 1994;114:119.CrossRefGoogle Scholar
  22. 22.
    Robinson RG, Jorge RE, Clarence-Smith K. Double-blind randomized treatment of poststroke depression using nefiracetam. J Neuropsychiatry Clin Neurosci. 2008;20:178–84.PubMedCrossRefGoogle Scholar
  23. 23.
    Kucukalic A, Bravo-Mehmedbasic A, Kulenovic AD, Suljic-Mehmedika E. Venlafaxine efficacy and tolerability in the treatment of post-stroke depression. Psychiatr Danub. 2007;19:56–60.PubMedGoogle Scholar
  24. 24.
    Choi-Kwon S, Choi J, Kwon SU, Kang DW, Kim JS. Fluoxetine improves the quality of life in patients with poststroke emotional disturbances. Cerebrovasc Dis. 2008;26(3):266–71.PubMedCrossRefGoogle Scholar
  25. 25.
    Choi-Kwon S, Han SW, Kwon SU, Kang DW, Choi JM, Kim JS. Fluoxetine treatment in poststroke depression, emotional incontinence, and anger proneness: a double-blind, placebo-controlled study. Stroke. 2006;37:156–61.PubMedCrossRefGoogle Scholar
  26. 26.
    Wiart L, Petit H, Joseph PA, Mazaux JM, Barat M. Fluoxetine in early post-stroke depression: a double-blind placebo-controlled study. Stroke. 2000;31:1829–32.PubMedCrossRefGoogle Scholar
  27. 27.
    Fruehwald S, Gatterbauer E, Rehak P, Baumhackl U. Early fluoxetine treatment of post-stroke depression—a three-month double-blind placebo-controlled study with open-label long-term follow up. J Neurol. 2003;250:347–51.PubMedCrossRefGoogle Scholar
  28. 28.
    Grade C, Redford B, Chrostowski J, et al. Methylphenidate in early poststroke recovery: a doubleblind, placebo-controlled study. Arch Phys Med Rehabil. 1998;79:1047–50.PubMedCrossRefGoogle Scholar
  29. 29.
    Tardy J, Pariente J, Leger A, et al. Methylphenidate modulates cerebral post-stroke reorganization. Neuroimage. 2006;33:913–22.PubMedCrossRefGoogle Scholar
  30. 30.
    Gonzalez-Torrecillas JL, Mendlewicz J, Lobo A. Effects of early treatment of poststroke depression on neuropsychological rehabilitation. Int Psychogeriatr. 1995;7:547–60.PubMedCrossRefGoogle Scholar
  31. 31.
    Gainotti G, Antonucci G, Marra C, Paolucci S. Relation between depression after stroke, antidepressant therapy and functional recovery. J Neurol Neurosurg Psychiatry. 2001;71:258–61.PubMedCrossRefGoogle Scholar
  32. 32.
    Miyai I, Reding MJ. Effects of antidepressants on functional recovery following stroke: a double-blind study. J Neurol Rehabil. 1998;12:5–13.Google Scholar
  33. 33.
    Narushima K, Chan KL, Kosier JT, Robinson RG. Does cognitive recovery after treatment of poststroke depression last? A 2-year follow-up of cognitive function associated with poststroke depression. Am J Psychiatry. 2003;160:1157–62.PubMedCrossRefGoogle Scholar
  34. 34.
    Dam M, Tonin P, De Boni A, et al. Effects of fluoxetine and maprotiline on functional recovery in poststroke hemiplegic patients undergoing rehabilitation therapy. Stroke. 1996;27:1211–4.PubMedCrossRefGoogle Scholar
  35. 35.
    Schmid AA, Kroenke K, Hendrie HC, Bakas T, Sutherland JM, Williams LS. Poststroke depression and treatment effects on functional outcomes. Neurology. 2011;76(11):1000–5.PubMedCrossRefGoogle Scholar
  36. 36.
    •• Chollet F, Tardy J, Albucher JF, Thalamas C, Berard E, Lamy C, Bejot Y, Deltour S, Jaillard A, Niclot P, Guillon B, Moulin T, Marque P, Pariente J, Arnaud C, Loubinoux I. Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial. Lancet Neurol. 2011;10(2):123–30. First trial demonstrating the positive effect of SSRI fluoxetine on motor deficit of patients with ischaemic stroke.Google Scholar
  37. 37.
    Acler M, Robol E, Fiaschi A, Manganotti P. A double blind placebo RCT to investigate the effects of serotonergic modulation on brain excitability and motor recovery in stroke patients. J Neurol. 2009;256(7):1152–8.PubMedCrossRefGoogle Scholar
  38. 38.
    Zittel S, Weiller C, Liepert J. Citalopram improves dexterity in chronic stroke patients. Neurorehabil Neural Repair. 2008;22:311–4.PubMedCrossRefGoogle Scholar
  39. 39.
    Pariente J, Loubinoux I, Carel C, et al. Fluoxetine modulates motor performance and cerebral activation of patients recovering from stroke. Ann Neurol. 2001;50:718–29.PubMedCrossRefGoogle Scholar
  40. 40.
    Gerdelat-Mas A, Loubinoux I, Tombari D, et al. Chronic administration of selective serotonin reuptake inhibitor (SSRI) paroxetine modulates human motor cortex excitability in healthy subjects. Neuroimage. 2005;27:314–22.PubMedCrossRefGoogle Scholar
  41. 41.
    Mikami K, Jorge RE, Adams HP Jr, Davis PH, Leira EC, Jang M, Robinson RG. Effect of antidepressants on the course of disability following stroke. Am J Geriatr Psychiatry. 2011.Google Scholar
  42. 42.
    Robinson RG, Jorge RE, Moser DJ, Acion L, Solodkin A, Small SL, Fonzetti P, Hegel M, Arndt S. Escitalopram and problem-solving therapy for prevention of poststroke depression: a randomized controlled trial. JAMA. 2008;299(20):2391–400.Google Scholar
  43. 43.
    Hackett ML, Anderson CS, House A, Halteh C. Interventions for preventing depression after stroke. Cochrane Database of Systematic Reviews 2008, Issue 3. Art. No.: CD003689. doi: 10.1002/14651858.CD003689.pub3.
  44. 44.
    Narushima K, Kosier JT, Robinson RG. Preventing poststroke depression. A 12-week double-blind randomized treatment trail and 21-month follow-up. J Nerv Ment Dis. 2002;190:296–303.PubMedCrossRefGoogle Scholar
  45. 45.
    Palomaki H, Kaste M, Berg A, Lonnqvist R, Lonnqvist J, Lehtihalmes M, Hares J. Prevention of poststroke depression: 1 year randomised placebo controlled double blind trial of mianserin with 6 month follow up after therapy. J Neurol Neurosurg Psychiatry. 1999;66:490–4.PubMedCrossRefGoogle Scholar
  46. 46.
    Zittel S, Weiller C, Liepert J. Reboxetine improves motor function in chronic stroke: A pilot study. J Neurol. 2007;254:197–201.PubMedCrossRefGoogle Scholar
  47. 47.
    Laska AC, von Arbin M, Kahan T, et al. Long-term antidepressant treatment with moclobemide for aphasia in acute stroke patients: a randomised, double-blind, placebo-controlled study. Cerebrovasc Dis. 2005;19:125–32.PubMedCrossRefGoogle Scholar
  48. 48.
    Jacobs BL, Fornal CA. Serotonin and motor activity. Curr Opin Neurobiol. 1997;7:820–5.PubMedCrossRefGoogle Scholar
  49. 49.
    Lim CM, Kim SW, Park JY, Kim C, Yoon SH, Lee JK. Fluoxetine affords robust neuroprotection in the postischemic brain via its anti-inflammatory effect. Neurosci Res. 2009;87:1037–45.CrossRefGoogle Scholar
  50. 50.
    Li WL, Cai HH, Wang B, et al. Chronic fluoxetine treatment improves ischemia-induced spatial cognitive deficits through increasing hippocampal neurogenesis after stroke. J Neurosci Res. 2009;87:112–22.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2012

Authors and Affiliations

  • F. Chollet
    • 1
    Email author
  • B. Acket
    • 1
  • N. Raposo
    • 1
  • J. F. Albucher
    • 1
  • I. Loubinoux
    • 2
  • J. Pariente
    • 1
  1. 1.Department of NeurologyUniversité Paul Sabatier, Purpan HospitalToulouseFrance
  2. 2.INSERM U 825Université Paul Sabatier Hopital PurpanToulouseFrance

Personalised recommendations